Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-11-12 09:03 am Sale | 2026-09-30 | 13G | OPUS GENETICS, INC. IRD | Adage Capital Management, L.P. | 2,254,996 2.710% | -3,774,779 (-62.60%) | Filing History |
| 2026-10-27 5:25 pm Purchase | 2026-09-30 | 13G | OPUS GENETICS, INC. IRD | BlackRock Inc. BLK | 5,044,847 6.100% | 5,044,847 (New Position) | Filing History |
| 2026-08-14 5:19 pm Purchase | 2026-06-30 | 13G | OPUS GENETICS, INC. IRD | Perceptive Advisors LLC | 9,233,710 9.990% | 403,565 (+4.57%) | Filing History |
| 2026-08-14 4:32 pm Purchase | 2026-06-30 | 13G | OPUS GENETICS, INC. IRD | Caligan Partners LP | 6,077,084 7.300% | 2,056 (+0.03%) | Filing History |
| 2026-08-14 06:03 am Purchase | 2026-06-30 | 13G | OPUS GENETICS, INC. IRD | BALYASNY ASSET MANAGEMENT L.P. | 5,480,210 6.640% | 369,837 (+7.24%) | Filing History |
| 2026-05-20 7:53 pm Sale | 2026-05-18 | 13D | OPUS GENETICS, INC. IRD | Foundation Fighting Blindness Retinal Degeneration Fund | 3,792,171 4.660% | -1,700,000 (-30.95%) | Filing History |
| 2026-05-15 4:40 pm Sale | 2026-03-31 | 13G | OPUS GENETICS, INC. IRD | Nantahala Capital Management, LLC | 4,839,225 6.510% | -2,284,281 (-32.07%) | Filing History |
| 2026-05-15 4:00 pm Purchase | 2026-03-31 | 13G | OPUS GENETICS, INC. IRD | Perceptive Advisors LLC | 8,830,145 9.990% | 1,655,991 (+23.08%) | Filing History |
| 2026-05-15 10:56 am Purchase | 2026-03-31 | 13G | OPUS GENETICS, INC. IRD | Caligan Partners LP | 6,075,028 8.500% | 6,075,028 (New Position) | Filing History |
| 2026-05-15 06:38 am Unchanged | 2026-03-31 | 13G | OPUS GENETICS, INC. IRD | BALYASNY ASSET MANAGEMENT L.P. | 5,110,373 7.180% | 0 (Unchanged) | Filing History |
| 2026-05-13 11:07 am Unchanged | 2026-05-12 | 13G | OPUS GENETICS, INC. IRD | BIOS Fund III LP | 3,683,429 4.530% | 0 (Unchanged) | Filing History |
| 2026-05-13 09:44 am Purchase | 2026-03-31 | 13G | OPUS GENETICS, INC. IRD | Adage Capital Management, L.P. | 6,029,775 8.470% | 6,029,775 (New Position) | Filing History |
| 2026-02-17 4:00 pm Purchase | 2025-12-31 | 13G | OPUS GENETICS, INC. IRD | Perceptive Advisors LLC | 7,174,154 9.990% | 2,663,653 (+59.05%) | Filing History |
| 2026-02-17 06:28 am Purchase | 2025-12-31 | 13G | OPUS GENETICS, INC. IRD | BALYASNY ASSET MANAGEMENT L.P. | 5,110,373 7.410% | 5,110,373 (New Position) | Filing History |
| 2026-02-13 5:06 pm Purchase | 2025-12-31 | 13G | OPUS GENETICS, INC. IRD | Nantahala Capital Management, LLC | 7,123,506 9.990% | 873,207 (+13.97%) | Filing History |
| 2025-12-11 8:52 pm Sale | 2025-12-09 | 13D | OPUS GENETICS, INC. IRD | Foundation Fighting Blindness Retinal Degeneration Fund | 5,492,171 8.000% | -4,000,000 (-42.14%) | Filing History |
| 2025-08-14 4:32 pm Purchase | 2025-06-30 | 13G | OPUS GENETICS, INC. IRD | Nantahala Capital Management, LLC | 6,250,299 9.990% | 1,552,643 (+33.05%) | Filing History |
| 2025-08-11 6:56 pm Purchase | 2025-05-05 | 13G | REIN THERAPEUTICS INC RNTX | BIOS Fund III LP | 3,683,429 6.200% | 3,683,429 (New Position) | Filing History |
| 2025-05-15 4:33 pm Purchase | 2025-03-31 | 13G | OPUS GENETICS, INC. IRD | Nantahala Capital Management, LLC | 4,697,656 9.990% | 4,697,656 (New Position) | Filing History |
| 2025-05-06 5:55 pm Purchase | 2025-04-30 | 13D | OPUS GENETICS, INC. IRD | Foundation Fighting Blindness Retinal Degeneration Fund | 9,492,171 15.900% | 6,927,419 (+270.10%) | Filing History |